StreetInsider.com News Articles

BofA Securities Reiterates Neutral Rating on Novo Nordisk (NOVOB:DC) (NVO)

Fri, 04 Sep 2026 06:07:51 -0400

BofA Securities analyst Sachin Jain reiterated a Neutral rating and DKK350.00 price target on Novo Nordisk (NOVOB:DC) (NYSE: NVO).

BofA Securities Reiterates Neutral Rating on Novo Nordisk (NOVOB:DC) (NVO)

Fri, 04 Sep 2026 06:07:51 -0400

BofA Securities analyst Sachin Jain reiterated a Neutral rating and DKK350.00 price target on Novo Nordisk (NOVOB:DC) (NYSE: NVO).

Form 6-K NOVO NORDISK A S For: Aug 31

Mon, 31 Aug 2026 09:11:00 -0400

si-local-file:///var/storage/secattach/20260831/27001996.html

Deutsche Bank cuts Novo Nordisk to Sell after earnings, shares dip

Thu, 27 Aug 2026 08:59:42 -0400

Investing.com -- Deutsche Bank downgraded Novo Nordisk (NYSE:NVO) (CSE:NOVOb) to Sell from Hold and cut its price target by 9% to 265 Danish crowns from 290 crowns, flagging persisting concerns over the company’s growth trajectory. The stock fell more than 3% in Copenhagen trading Thursday.

Analyst Emmanuel Papadakis said the downgrade follows Novo’s "mixed" second-quarter earnings earlier this month, along with subsequent takeaways from a London sellside meeting, Deutsche Bank’s CEO non-deal roadshow in Frankfurt, and recent prescription trends.

Novo raised its full-year profit and sales outlook in a surprise early earnings release, with both metrics now seen in a range

Deutsche Bank cuts Novo Nordisk to Sell after earnings, shares dip

Thu, 27 Aug 2026 08:59:42 -0400

Novo raised its full-year profit and sales outlook in a surprise early earnings release, with both metrics now seen in a range

Novo Nordisk seeks China approval for oral Wegovy drug

Thu, 27 Aug 2026 08:27:14 -0400

Investing.com -- Novo Nordisk said on Thursday that China's drug regulator accepted its application to sell the oral version of its weight-loss drug Wegovy. The Danish drugmaker aims to compete with rival Eli Lilly in the world's second-largest pharmaceutical market.

Novo Nordisk, Eli Lilly, Pfizer, and local company Innovent Biologics are competing for market share with their versions of once-weekly GLP-1 weight-loss injections in China. The country's National Health Commission said the rate of overweight or obese people could reach more than 65% by 2030.

Both Novo Nordisk and Eli Lilly believe weight-loss pills could attract patients who are reluctant to use

Novo Nordisk seeks China approval for oral Wegovy drug

Thu, 27 Aug 2026 08:27:14 -0400

Both Novo Nordisk and Eli Lilly believe weight-loss pills could attract patients who are reluctant to use

Deutsche Bank Downgrades Novo Nordisk (NOVOB:DC) (NVO) to Sell

Thu, 27 Aug 2026 04:23:56 -0400

Deutsche Bank analyst Emmanuel Papadakis downgraded Novo Nordisk (NOVOB:DC) (NYSE: NVO) from Hold to Sell with a price target of DKK265.00 (from DKK290.00).

Deutsche Bank Downgrades Novo Nordisk (NOVOB:DC) (NVO) to Sell

Thu, 27 Aug 2026 04:23:56 -0400

Deutsche Bank analyst Emmanuel Papadakis downgraded Novo Nordisk (NOVOB:DC) (NYSE: NVO) from Hold to Sell with a price target of DKK265.00 (from DKK290.00).

Deutsche Bank Downgrades Novo Nordisk (NOVOB:DC) (NVO) to Sell

Thu, 27 Aug 2026 04:23:56 -0400

Deutsche Bank analyst Emmanuel Papadakis downgraded Novo Nordisk (NOVOB:DC) (NYSE: NVO) from Hold to Sell with a price target of DKK265.00 (from DKK290.00).

Deutsche Bank Downgrades Novo Nordisk (NOVOB:DC) (NVO) to Sell

Thu, 27 Aug 2026 04:23:56 -0400

Deutsche Bank analyst Emmanuel Papadakis downgraded Novo Nordisk (NOVOB:DC) (NYSE: NVO) from Hold to Sell with a price target of DKK265.00 (from DKK290.00).

Deutsche Bank Downgrades Novo Nordisk (NOVOB:DC) (NVO) to Sell

Thu, 27 Aug 2026 04:23:56 -0400

Deutsche Bank analyst Emmanuel Papadakis downgraded Novo Nordisk (NOVOB:DC) (NYSE: NVO) from Hold to Sell with a price target of DKK265.00 (from DKK290.00).

Deutsche Bank Downgrades Novo Nordisk (NOVOB:DC) (NVO) to Sell

Thu, 27 Aug 2026 04:23:56 -0400

Deutsche Bank analyst Emmanuel Papadakis downgraded Novo Nordisk (NOVOB:DC) (NYSE: NVO) from Hold to Sell with a price target of DKK265.00 (from DKK290.00).

PepsiCo Scraps Coverage of Weight-Loss Drugs for Employees - Bloomberg

Tue, 25 Aug 2026 13:54:46 -0400

(Updated - August 25, 2026 1:54 PM EDT)

PepsiCo Scraps Coverage of Weight-Loss Drugs for Employees - Bloomberg

Tue, 25 Aug 2026 13:54:46 -0400

(Updated - August 25, 2026 1:54 PM EDT)

PepsiCo Scraps Coverage of Weight-Loss Drugs for Employees - Bloomberg

Tue, 25 Aug 2026 13:54:46 -0400

(Updated - August 25, 2026 1:54 PM EDT)

PepsiCo Scraps Coverage of Weight-Loss Drugs for Employees - Bloomberg

Tue, 25 Aug 2026 13:54:46 -0400

(Updated - August 25, 2026 1:54 PM EDT)

PepsiCo Scraps Coverage of Weight-Loss Drugs for Employees - Bloomberg

Novo Nordisk (NOVOB:DC) (NVO) PT Raised to DKK275 at JPMorgan